DEBORAH J ANDREWS

CIK 1325697 · Interim Co-CEO and CFO · last filed 2026-05-19

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$341.0K

Companies

3

Total Filings

54

Lifetime Open-Market Net

-$6.82M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
STAA Interim Co-CEO and CFO 10,466 $28.37 $296.9K -$6.79M 36 2026-05-19
LCTX Director 34,720 $1.27 $44.1K -$56.1K 7 2025-07-02
Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Director 10,000 $27.7K 10 2018-09-13

Recent Filings · Page 5 of 6

54 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2013-08-12 STAA Sell (S) −9,079 -$105.5K EDGAR
2013-08-07 STAA Sell (S) −11,721 -$138.2K EDGAR
2013-05-09 STAA Sell (S) −5,000 -$44.8K EDGAR
2013-03-06 STAA Grant (A) +7,500 $0 EDGAR
2012-12-11 STAA Exer (M) +3,000 $10.8K EDGAR
2012-03-06 STAA Grant (A) +7,500 $0 EDGAR
2011-08-19 STAA Sell (S) −30,000 -$197.6K EDGAR
2011-03-17 STAA Grant (A) +7,500 $0 EDGAR
2011-03-04 STAA Grant (A) +4,000 $0 EDGAR
2010-12-17 STAA Grant (A) $0 EDGAR
Showing 4150 of 54
Page 5 of 6
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.